All questionsDosing and administration: Zepbound (tirzepatide), all indications6 questions · 1 sourceDosingWhat is the maximum dose of Zepbound?“The maximum dosage of ZEPBOUND for all indications is 15 mg injected subcutaneously once weekly.” (opens the source at this quote in a new tab)CopyFlagWhat if a Zepbound dose is missed?“If a dose is missed, instruct patients to administer ZEPBOUND as soon as possible within 4 days (96 hours) after the missed dose. If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day. In each case, patients can then resume their regular once weekly dosing schedule.” (opens the source at this quote in a new tab)CopyFlagCan the Zepbound injection day be changed?“The day of weekly administration can be changed, if necessary, as long as the time between the two doses is at least 3 days (72 hours).” (opens the source at this quote in a new tab)CopyFlagAdministrationDoes Zepbound need to be taken with food?“Administer ZEPBOUND once weekly at any time of day, with or without meals.” (opens the source at this quote in a new tab)CopyFlagHow and where is Zepbound injected?“Inspect ZEPBOUND visually before use. It should appear clear and colorless to slightly yellow. Do not use ZEPBOUND if particulate matter or discoloration is seen. Administer ZEPBOUND in combination with a reduced-calorie diet and increased physical activity. Administer ZEPBOUND once weekly at any time of day, with or without meals. Inject ZEPBOUND subcutaneously in the abdomen, thigh, or another person should inject in the back of the upper arm. Rotate injection sites with each dose.” (opens the source at this quote in a new tab)CopyFlag“Similar exposure was achieved with subcutaneous administration of tirzepatide in the abdomen, thigh, or upper arm.” (opens the source at this quote in a new tab)CopyFlagWhat is the difference between Zepbound vials, single-dose pens, and the KwikPen?“Injection: Clear, colorless to slightly yellow solution in pre-filled single-dose pens, single-dose vials, multi-dose vials, or single-patient-use KwikPens, each available in the following strengths. The multi-dose vials and single-patient-use KwikPen each contain 4 doses: Single-dose Pen or Vial 2.5 mg/0.5 mL 5 mg/0.5 mL 7.5 mg/0.5 mL 10 mg/0.5 mL 12.5 mg/0.5 mL 15 mg/0.5 mL Multi-dose Vial (4 doses per vial) Dose per Injection Total Strength per Total Volume Strength per mL 2.5 mg/0.6 mL 10 mg/2.4 mL 4.17 mg/mL 5 mg/0.6 mL 20 mg/2.4 mL 8.33 mg/mL 7.5 mg/0.6 mL 30 mg/2.4 mL 12.5 mg/mL 10 mg/0.6 mL 40 mg/2.4 mL 16.7 mg/mL 12.5 mg/0.6 mL 50 mg/2.4 mL 20.8 mg/mL 15 mg/0.6 mL 60 mg/2.4 mL 25 mg/mL Single-Patient-Use KwikPen (4 doses per KwikPen) Dose per Injection Total Strength per Total Volume Strength per mL 2.5 mg 10 mg/2.4 mL 4.17 mg/mL 5 mg 20 mg/2.4 mL 8.33 mg/mL 7.5 mg 30 mg/2.4 mL 12.5 mg/mL 10 mg 40 mg/2.4 mL 16.7 mg/mL 12.5 mg 50 mg/2.4 mL 20.8 mg/mL 15 mg 60 mg/2.4 mL 25 mg/mL” (opens the source at this quote in a new tab)CopyFlag“Inform patients and their caregiver(s) which ZEPBOUND presentation (e.g., vial, prefilled single-dose pen, single-patient-use KwikPen) they will receive and ensure they receive training appropriate for that specific presentation. If the prescribed ZEPBOUND presentation changes, ensure patients and caregivers receive appropriate training and instruct them to consult the Instructions for Use for the newly prescribed presentation.” (opens the source at this quote in a new tab)CopyFlag“ZEPBOUND KwikPen is not recommended for self-administration by those who are visually impaired. Instruct patients using ZEPBOUND vials to use a syringe appropriate for dose administration (e.g., a 1 mL syringe capable of measuring a 0.5 mL or 0.6 mL dose) and always use a new syringe and needle for each injection.” (opens the source at this quote in a new tab)CopyFlag“Each single-patient-use KwikPen contains additional volume to allow for device priming.” (opens the source at this quote in a new tab)CopyFlag“Never share ZEPBOUND KwikPen between patients, even if the pen needle is changed. Sharing poses a risk for transmission of blood-borne pathogens.” (opens the source at this quote in a new tab)CopyFlag